Forced expression of S100A10 reduces sensitivity to oxaliplatin in colorectal cancer cells

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: Individual responses to oxaliplatin (L-OHP)-based chemotherapy remain unpredictable. Our recent proteomics studies have demonstrated that intracellular protein expression levels of S100A10 are significantly correlated with the sensitivity of colorectal cancer (CRC) cells to L-OHP, but not 5-FU, suggesting that S100A10 is a candidate predictive marker for the response to L-OHP. In this study, we investigated whether S100A10 is involved in L-OHP sensitivity or not.Results: Forced expression of S100A10 in COLO-320 CRC cells significantly increased the 50% inhibitory concentration (IC50) for L-OHP (P = 0.003), but did not change that for 5-FU, indicating that S100A10 is more specific to L-OHP than 5-FU. Silencing of the S100A10 gene showed no apparent effect on sensitivity to L-OHP in HT29 cells. Silencing of the annexin A2 (a binding partner of S100A10) gene alone downregulated both annexin A2 and S100A10 protein levels, with no change in S100A10 gene expression. However, original levels of intact S100A10 protein in CRC cells positively correlated with S100A10 mRNA levels (P = 0.002, R = 0.91).Conclusions: The present results have shown that protein expression of S100A10 was associated with resistance to L-OHP, but not 5-FU, supporting the hypothesis that S100A10 expression may predict L-OHP sensitivity. Thus, our present study provides basic findings to support that S100A10 expression can be used as a predictive marker for tumor sensitivity to L-OHP.

Original languageEnglish
Article number26
JournalProteome Science
Volume12
Issue number1
DOIs
Publication statusPublished - 2014 May 9

Fingerprint

oxaliplatin
Fluorouracil
Colorectal Neoplasms
Cells
Annexin A2
Inhibitory Concentration 50
Genes
HT29 Cells
Chemotherapy
Gene Silencing
Tumor Biomarkers
Gene expression
Proteomics
Proteins
Down-Regulation
Gene Expression
Drug Therapy
Messenger RNA

Keywords

  • Annexin A2
  • Colorectal cancer
  • Oxaliplatin
  • S100A10

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology

Cite this

Forced expression of S100A10 reduces sensitivity to oxaliplatin in colorectal cancer cells. / Suzuki, Sayo; Tanigawara, Yusuke.

In: Proteome Science, Vol. 12, No. 1, 26, 09.05.2014.

Research output: Contribution to journalArticle

@article{ced271f96904472f8a56f3e62d91538f,
title = "Forced expression of S100A10 reduces sensitivity to oxaliplatin in colorectal cancer cells",
abstract = "Background: Individual responses to oxaliplatin (L-OHP)-based chemotherapy remain unpredictable. Our recent proteomics studies have demonstrated that intracellular protein expression levels of S100A10 are significantly correlated with the sensitivity of colorectal cancer (CRC) cells to L-OHP, but not 5-FU, suggesting that S100A10 is a candidate predictive marker for the response to L-OHP. In this study, we investigated whether S100A10 is involved in L-OHP sensitivity or not.Results: Forced expression of S100A10 in COLO-320 CRC cells significantly increased the 50{\%} inhibitory concentration (IC50) for L-OHP (P = 0.003), but did not change that for 5-FU, indicating that S100A10 is more specific to L-OHP than 5-FU. Silencing of the S100A10 gene showed no apparent effect on sensitivity to L-OHP in HT29 cells. Silencing of the annexin A2 (a binding partner of S100A10) gene alone downregulated both annexin A2 and S100A10 protein levels, with no change in S100A10 gene expression. However, original levels of intact S100A10 protein in CRC cells positively correlated with S100A10 mRNA levels (P = 0.002, R = 0.91).Conclusions: The present results have shown that protein expression of S100A10 was associated with resistance to L-OHP, but not 5-FU, supporting the hypothesis that S100A10 expression may predict L-OHP sensitivity. Thus, our present study provides basic findings to support that S100A10 expression can be used as a predictive marker for tumor sensitivity to L-OHP.",
keywords = "Annexin A2, Colorectal cancer, Oxaliplatin, S100A10",
author = "Sayo Suzuki and Yusuke Tanigawara",
year = "2014",
month = "5",
day = "9",
doi = "10.1186/1477-5956-12-26",
language = "English",
volume = "12",
journal = "Proteome Science",
issn = "1477-5956",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Forced expression of S100A10 reduces sensitivity to oxaliplatin in colorectal cancer cells

AU - Suzuki, Sayo

AU - Tanigawara, Yusuke

PY - 2014/5/9

Y1 - 2014/5/9

N2 - Background: Individual responses to oxaliplatin (L-OHP)-based chemotherapy remain unpredictable. Our recent proteomics studies have demonstrated that intracellular protein expression levels of S100A10 are significantly correlated with the sensitivity of colorectal cancer (CRC) cells to L-OHP, but not 5-FU, suggesting that S100A10 is a candidate predictive marker for the response to L-OHP. In this study, we investigated whether S100A10 is involved in L-OHP sensitivity or not.Results: Forced expression of S100A10 in COLO-320 CRC cells significantly increased the 50% inhibitory concentration (IC50) for L-OHP (P = 0.003), but did not change that for 5-FU, indicating that S100A10 is more specific to L-OHP than 5-FU. Silencing of the S100A10 gene showed no apparent effect on sensitivity to L-OHP in HT29 cells. Silencing of the annexin A2 (a binding partner of S100A10) gene alone downregulated both annexin A2 and S100A10 protein levels, with no change in S100A10 gene expression. However, original levels of intact S100A10 protein in CRC cells positively correlated with S100A10 mRNA levels (P = 0.002, R = 0.91).Conclusions: The present results have shown that protein expression of S100A10 was associated with resistance to L-OHP, but not 5-FU, supporting the hypothesis that S100A10 expression may predict L-OHP sensitivity. Thus, our present study provides basic findings to support that S100A10 expression can be used as a predictive marker for tumor sensitivity to L-OHP.

AB - Background: Individual responses to oxaliplatin (L-OHP)-based chemotherapy remain unpredictable. Our recent proteomics studies have demonstrated that intracellular protein expression levels of S100A10 are significantly correlated with the sensitivity of colorectal cancer (CRC) cells to L-OHP, but not 5-FU, suggesting that S100A10 is a candidate predictive marker for the response to L-OHP. In this study, we investigated whether S100A10 is involved in L-OHP sensitivity or not.Results: Forced expression of S100A10 in COLO-320 CRC cells significantly increased the 50% inhibitory concentration (IC50) for L-OHP (P = 0.003), but did not change that for 5-FU, indicating that S100A10 is more specific to L-OHP than 5-FU. Silencing of the S100A10 gene showed no apparent effect on sensitivity to L-OHP in HT29 cells. Silencing of the annexin A2 (a binding partner of S100A10) gene alone downregulated both annexin A2 and S100A10 protein levels, with no change in S100A10 gene expression. However, original levels of intact S100A10 protein in CRC cells positively correlated with S100A10 mRNA levels (P = 0.002, R = 0.91).Conclusions: The present results have shown that protein expression of S100A10 was associated with resistance to L-OHP, but not 5-FU, supporting the hypothesis that S100A10 expression may predict L-OHP sensitivity. Thus, our present study provides basic findings to support that S100A10 expression can be used as a predictive marker for tumor sensitivity to L-OHP.

KW - Annexin A2

KW - Colorectal cancer

KW - Oxaliplatin

KW - S100A10

UR - http://www.scopus.com/inward/record.url?scp=84901270630&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901270630&partnerID=8YFLogxK

U2 - 10.1186/1477-5956-12-26

DO - 10.1186/1477-5956-12-26

M3 - Article

VL - 12

JO - Proteome Science

JF - Proteome Science

SN - 1477-5956

IS - 1

M1 - 26

ER -